Biomarin Pharmaceutical (BMRN) Return on Capital Employed (2010 - 2026)

Biomarin Pharmaceutical has disclosed Return on Capital Employed across 17 years of filings, most recently posting 4.32% for Q1 2026.

• Quarterly Return on Capital Employed fell 530.0% year-over-year to 4.32% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 4.32% (down 530.0% YoY) and the FY2025 annual result came in at 6.27%, down 141.0% from the prior year.
• Return on Capital Employed declined to 4.32% in Q1 2026, from 5.98% in the prior quarter.
• Over five years, Return on Capital Employed peaked at 11.73% in Q2 2025 and troughed at 0.54% in Q1 2022.
• A 5-year average of 4.58% and a median of 3.67% in 2024 frame the typical range for Return on Capital Employed.
• Annual changes were most pronounced in 2025 — Return on Capital Employed soared 721 bps — and 2026, when it tumbled 530 bps.
• Tracing BMRN's Return on Capital Employed over 5 years: stood at 2.81% in 2022, then rose by 18 bps to 3.3% in 2023, then surged by 132 bps to 7.67% in 2024, then declined by 22 bps to 5.98% in 2025, then dropped by 28 bps to 4.32% in 2026.
• Business Quant data shows BMRN's Return on Capital Employed at 4.32% in Q1 2026, 5.98% in Q4 2025, and 9.14% in Q3 2025.